US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AI Healthcare

741.54

+16.452.27%

Number of Gainers:4

Number of Losers:- -

Number of Flat:- -

PE:- -

High:755.81

Open:728.84

Low:718.07

Close:725.09

Volume:34.78M

Turnover:1.39B

Market Cap:22.56B

Float Cap:16.89B

Loading ...

Theodore Leonsis, Director, Reports Disposal of Common Shares of Tempus AI Inc

Mixed options sentiment in tempus AI Inc Class A with shares up 3.58%

Largest borrow rate increases among liquid names

CureVac Reports Decrease in Net Financial Result for H1 2025; R&D Expenses Rise Amid Strategic Restructuring

Beam Therapeutics Shares up 1.5% Premarket After U.S. FDA's Tag for Sickle Cell Disease Therapy

THOMSON REUTERS

Beam Therapeutics Secures FDA Regenerative Medicine Advanced Therapy Designation for BEAM-101 in Sickle Cell Disease Treatment

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Beam-101 for the Treatment of Sickle Cell Disease

THOMSON REUTERS

Christopher Gibson, CEO, Reports Disposal of Recursion Pharmaceuticals Inc. Common Shares

tempus AI Inc Class A call volume above normal and directionally bullish

Tempus AI, Inc. Class A (TEM) Receives a Hold from Piper Sandler

Tempus AI Inc : JP Morgan Raises Target Price to $60 From $55

THOMSON REUTERS

Cathie Wood’s Friday Flurry: Buys TTD and CRSP, Sells Roblox and Palantir Stocks

Crispr Therapeutics Faces Stock Dip Amid Promising Developments

Tempus AI Reports Strong Q2 2025 Growth

Director Makes Bold Move with Major Stock Purchase in Crispr Therapeutics AG!

Tempus AI Inc. Announces Corporate Actions Following Majority Stockholder Approval

Crispr Therapeutics’ CTX112 Study: A New Frontier in Autoimmune Disease Treatment

Tempus AI Shares Rise 3.8% After Co Lifts Annual Revenue Outlook

THOMSON REUTERS

Analysts Conflicted on These NA Names: Tempus AI, Inc. Class A (TEM) and CG Oncology, Inc. (CGON)

Tempus AI Shares up 8.6% After Co Raises FY Revenue Forecast

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":741.5427,"timestamp":1755287999999,"preClose":725.0915,"halted":0,"volume":34778851,"delay":0,"changeRate":0.022688,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":16.451233,"latestTime":"08-15 16:00:00 EDT","open":728.844,"high":755.81006,"low":718.0679,"amount":1388401514.81892,"amplitude":0.052052,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1755504000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.511144,"peRate":-12.809221,"turnoverRate":0.049905,"increases":4,"decrements":0,"flats":0,"marketCap":22560802048,"floatMarketCap":16888537344},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":755.81006,"amplitude":0.052052,"preClose":725.0915,"low":718.0679,"pbRate":"5.511144","latestPrice":741.5427,"volume":34778851,"delay":0,"open":728.844,"prevYearClose":530.4984,"prevWeekClose":657.3895,"prevMonthClose":663.6607,"prevQuarterClose":637.8218,"fiveDayClose":657.3895,"twentyDayClose":719.1298,"sixtyDayClose":591.4469,"secType":"PLATE","market":"US","turnoverRate":0.049905,"peRate":-12.809221,"marketCap":22560802048,"floatMarketCap":16888537344,"timestamp":1755287999999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":4,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559944298","title":"Theodore Leonsis, Director, Reports Disposal of Common Shares of Tempus AI Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2559944298","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559944298?lang=en_us&edition=fundamental","pubTime":"2025-08-16 09:22","pubTimestamp":1755307355,"startTime":"0","endTime":"0","summary":"Theodore Leonsis, a Director at Tempus AI Inc., reported a disposal of common shares of Tempus AI Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250816:nNDL7rxdVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","LU1861558580.USD","LU1861559042.SGD","TEM","BK4613","BK4121"],"gpt_icon":1},{"id":"2559945114","title":"Mixed options sentiment in tempus AI Inc Class A with shares up 3.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559945114","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559945114?lang=en_us&edition=fundamental","pubTime":"2025-08-16 03:25","pubTimestamp":1755285911,"startTime":"0","endTime":"0","summary":"Mixed options sentiment in tempus AI Inc Class A (TEM), with shares up $2.56, or 3.58%, near $74.15. Options volume running well above average with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-tempus-ai-inc-class-a-with-shares-up-3-58-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-tempus-ai-inc-class-a-with-shares-up-3-58-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","LU1861558580.USD","LU1861559042.SGD","TEM","BK4611","BK4613"],"gpt_icon":0},{"id":"2559149369","title":"Largest borrow rate increases among liquid names","url":"https://stock-news.laohu8.com/highlight/detail?id=2559149369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559149369?lang=en_us&edition=fundamental","pubTime":"2025-08-15 20:45","pubTimestamp":1755261916,"startTime":"0","endTime":"0","summary":"Latest data shows the largest indicative borrow rate increases among liquid option names include: Recursion Pharmaceuticals (RXRX) 41.81% +2.54, Po...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/largest-borrow-rate-increases-among-liquid-names-thefly-57?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/largest-borrow-rate-increases-among-liquid-names-thefly-57?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4611","BK4539","BK4139","BK4609","RXRX"],"gpt_icon":0},{"id":"2559954919","title":"CureVac Reports Decrease in Net Financial Result for H1 2025; R&D Expenses Rise Amid Strategic Restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2559954919","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559954919?lang=en_us&edition=fundamental","pubTime":"2025-08-15 19:28","pubTimestamp":1755257282,"startTime":"0","endTime":"0","summary":"CureVac Reports Decrease in Net Financial Result for H1 2025; R&D Expenses Rise Amid Strategic Restructuring               CureVac NV has released its financial results for the second quarter and firs","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nNDL7ts9MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","BK4588","BK4535","BK4568","CRSP","CVAC","LU1861559042.SGD","BK4551","BK4611","LU1861558580.USD","BK4548","BK4585","BNTX"],"gpt_icon":0},{"id":"2559518979","title":"Beam Therapeutics Shares up 1.5% Premarket After U.S. FDA's Tag for Sickle Cell Disease Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2559518979","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559518979?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:09","pubTimestamp":1755169784,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nL4N3U60PE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BEAM","BK4139","BK4556","BK4535","BK4611","BK4505"],"gpt_icon":0},{"id":"2559959168","title":"Beam Therapeutics Secures FDA Regenerative Medicine Advanced Therapy Designation for BEAM-101 in Sickle Cell Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2559959168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559959168?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:00","pubTimestamp":1755169217,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Secures FDA Regenerative Medicine Advanced Therapy Designation for BEAM-101 in Sickle Cell Disease Treatment. Beam Therapeutics Inc. has announced that the U.S. Food and Drug Administration  has granted Regenerative Medicine Advanced Therapy  designation to its investigational genetically modified cell therapy, BEAM-101, for the treatment of sickle cell disease. This designation, following the earlier orphan drug designation in June, underscores the potential of BEAM-101 as a transformative therapy for severe sickle cell disease. The RMAT designation will facilitate enhanced collaboration with the FDA as Beam Therapeutics progresses toward a Biologics License Application  filing. With updated data from the BEACON Phase 1/2 trial expected by the end of the year, Beam Therapeutics continues to focus on delivering this promising treatment to patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDLbgk2sF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","LU2210150020.SGD","BK4139","BK4588","BK4112","IE00BKPKM429.USD","LU0314104364.USD","LU2210149790.SGD","NDAQ","BK4556","BK4535","IE00BGHQF748.EUR","BEAM","BK4585","BK4505","IE00B3QW5Z07.USD","LU2095319765.USD","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2559295919","title":"Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Beam-101 for the Treatment of Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2559295919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559295919?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:00","pubTimestamp":1755169202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nTUA7FYQGX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4611","BK4535","BK4585","BK4139","BEAM","BK4588","BK4505"],"gpt_icon":0},{"id":"2559493837","title":"Christopher Gibson, CEO, Reports Disposal of Recursion Pharmaceuticals Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2559493837","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559493837?lang=en_us&edition=fundamental","pubTime":"2025-08-14 09:03","pubTimestamp":1755133434,"startTime":"0","endTime":"0","summary":"Christopher Gibson, Chief Executive Officer and Director of Recursion Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDLbS05hf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4609","RXRX","BK4611","BK4548","BK4139"],"gpt_icon":1},{"id":"2559398361","title":"tempus AI Inc Class A call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2559398361","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559398361?lang=en_us&edition=fundamental","pubTime":"2025-08-13 23:45","pubTimestamp":1755099913,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in tempus AI (TEM) Inc Class A with 45,265 calls trading, 2x expected, and implied vol increasing over 1 point to 72.6...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-inc-class-a-call-volume-above-normal-and-directionally-bullish-thefly-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-inc-class-a-call-volume-above-normal-and-directionally-bullish-thefly-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4613","LU1861558580.USD","TEM","BK4611","LU1861559042.SGD"],"gpt_icon":0},{"id":"2558301651","title":"Tempus AI, Inc. Class A (TEM) Receives a Hold from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2558301651","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558301651?lang=en_us&edition=fundamental","pubTime":"2025-08-11 18:38","pubTimestamp":1754908704,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Westenberg maintained a Hold rating on Tempus AI, Inc. Class A today and set a price target of $70.00. The company’s sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/tempus-ai-inc-class-a-tem-receives-a-hold-from-piper-sandler-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/tempus-ai-inc-class-a-tem-receives-a-hold-from-piper-sandler-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4611","TEM","BK4613","LU1861559042.SGD","BK4121"],"gpt_icon":0},{"id":"2558635027","title":"Tempus AI Inc : JP Morgan Raises Target Price to $60 From $55","url":"https://stock-news.laohu8.com/highlight/detail?id=2558635027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558635027?lang=en_us&edition=fundamental","pubTime":"2025-08-11 12:13","pubTimestamp":1754885590,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nFWN3U201P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","LU1861558580.USD","BK4611","BK4613","BK4121","TEM"],"gpt_icon":0},{"id":"2558768361","title":"Cathie Wood’s Friday Flurry: Buys TTD and CRSP, Sells Roblox and Palantir Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2558768361","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558768361?lang=en_us&edition=fundamental","pubTime":"2025-08-10 12:56","pubTimestamp":1754801804,"startTime":"0","endTime":"0","summary":"Popular investor Cathie Wood’s ARK Invest ETFs made several changes to their holdings on Friday, August 8. The firm bought shares of ad-tech compan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/cathie-woods-friday-flurry-buys-ttd-and-crsp-sells-roblox-and-palantir-stocks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/cathie-woods-friday-flurry-buys-ttd-and-crsp-sells-roblox-and-palantir-stocks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2264538146.SGD","BK4556","CRSP","TTD","BK4528","LU0786609619.USD","BK4535","LU1064131342.USD","LU1861558580.USD","BK4548","LU2543165471.USD","BK4085","BK4588","BK4543","BK4613","PLTR","LU1548497426.USD","BK4023","IE00B894F039.SGD","RBLX","BK4598","BK4547","LU1988902786.USD","BK4565","LU2357305700.SGD","BK4551","BK4585","BK4544","LU1720051108.HKD","LU1861559042.SGD","BK4139","BK4554","IE00B19Z9Z06.USD","BK4009","LU0348723411.USD","IE00BZ9MQY76.HKD","ARKK","LU1720051017.SGD","IE00B19Z9P08.USD","BK4611"],"gpt_icon":0},{"id":"2558713504","title":"Crispr Therapeutics Faces Stock Dip Amid Promising Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2558713504","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558713504?lang=en_us&edition=fundamental","pubTime":"2025-08-09 22:03","pubTimestamp":1754748206,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics AG ( ($CRSP) ) has fallen by -7.70%. Read on to learn why. Crispr Therapeutics AG has experienced a notable stock price decline...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/crispr-therapeutics-faces-stock-dip-amid-promising-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/crispr-therapeutics-faces-stock-dip-amid-promising-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LU1861558580.USD","BK4588","BK4585","LENZ","BK4556","BK4611","LU1861559042.SGD","BK4139","CRSP"],"gpt_icon":0},{"id":"2558506847","title":"Tempus AI Reports Strong Q2 2025 Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2558506847","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558506847?lang=en_us&edition=fundamental","pubTime":"2025-08-09 12:20","pubTimestamp":1754713239,"startTime":"0","endTime":"0","summary":"Tempus AI, Inc. Class A ( ($TEM) ) has released its Q2 earnings. Here is a breakdown of the information Tempus AI, Inc. Class A presented to its in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tempus-ai-reports-strong-q2-2025-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tempus-ai-reports-strong-q2-2025-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","LU1861559042.SGD","LU1861558580.USD","BK4611","BK4613","TEM"],"gpt_icon":0},{"id":"2558034185","title":"Director Makes Bold Move with Major Stock Purchase in Crispr Therapeutics AG!","url":"https://stock-news.laohu8.com/highlight/detail?id=2558034185","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558034185?lang=en_us&edition=fundamental","pubTime":"2025-08-09 10:09","pubTimestamp":1754705370,"startTime":"0","endTime":"0","summary":"New insider activity at Crispr Therapeutics AG ( ($CRSP) ) has taken place on August 8, 2025. Director Douglas A Treco has made a significant inves...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-stock-purchase-in-crispr-therapeutics-ag-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-stock-purchase-in-crispr-therapeutics-ag-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4210","AG","LU1861558580.USD","CRSP","BK4556","LENZ","BK4007","BK4539","BK4139","LU1861559042.SGD","BK4611","BK4588","BK4585"],"gpt_icon":0},{"id":"2558574441","title":"Tempus AI Inc. Announces Corporate Actions Following Majority Stockholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2558574441","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558574441?lang=en_us&edition=fundamental","pubTime":"2025-08-09 04:05","pubTimestamp":1754683547,"startTime":"0","endTime":"0","summary":"Tempus AI, Inc., a Nevada corporation, has announced that stockholders holding a majority of the voting power have approved certain actions. These actions, supported by the Majority Holder, are part of the company's ongoing strategic initiatives. The decisions reflect Tempus AI's commitment to evolving and aligning with its long-term vision. Eric Lefkofsky, the Chief Executive Officer, Founder, and Chairman of Tempus AI, expressed confidence in the direction set by the recent approvals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nNDL16j47F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEM","LU1861558580.USD","BK4611","BK4121","LU1861559042.SGD","BK4613"],"gpt_icon":1},{"id":"2558576113","title":"Crispr Therapeutics’ CTX112 Study: A New Frontier in Autoimmune Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2558576113","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558576113?lang=en_us&edition=fundamental","pubTime":"2025-08-09 00:23","pubTimestamp":1754670238,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics (($CRSP)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase 1 Dose Evaluat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crispr-therapeutics-ctx112-study-a-new-frontier-in-autoimmune-disease-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crispr-therapeutics-ctx112-study-a-new-frontier-in-autoimmune-disease-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NFC.U","BK4139","LU1861558580.USD","BK4611","LENZ","BK4585","BK4007","BK4588","LU1861559042.SGD","CRSP","BK4539","BK4556"],"gpt_icon":0},{"id":"2557575900","title":"Tempus AI Shares Rise 3.8% After Co Lifts Annual Revenue Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2557575900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557575900?lang=en_us&edition=fundamental","pubTime":"2025-08-08 23:50","pubTimestamp":1754668239,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nFWN3U0188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","LU1861558580.USD","LU1861559042.SGD","BK4121","BK4613","TEM"],"gpt_icon":0},{"id":"2557957555","title":"Analysts Conflicted on These NA Names: Tempus AI, Inc. Class A (TEM) and CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2557957555","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557957555?lang=en_us&edition=fundamental","pubTime":"2025-08-08 23:30","pubTimestamp":1754667014,"startTime":"0","endTime":"0","summary":"Companies in the NA sector have received a lot of coverage today as analysts weigh in on Tempus AI, Inc. Class A (TEM – Research Report) and CG Onc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-na-names-tempus-ai-inc-class-a-tem-and-cg-oncology-inc-cgon-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-na-names-tempus-ai-inc-class-a-tem-and-cg-oncology-inc-cgon-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4121","LU1861558580.USD","NA","BK4611","TEM","BK4135","LU1861559042.SGD","CG","CGON","BK4141","IE00B3QW5Z07.USD","BK4613","BK4139"],"gpt_icon":0},{"id":"2557527118","title":"Tempus AI Shares up 8.6% After Co Raises FY Revenue Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2557527118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557527118?lang=en_us&edition=fundamental","pubTime":"2025-08-08 21:33","pubTimestamp":1754660037,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL4N3U01N9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","LU1861558580.USD","TEM","LU1861559042.SGD","BK4121","BK4613"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":57,"code":"91000000","status":"200"}]}}